Urology-led pathway for haematuria gains traction with GPs
Cxbladder’s suite of non-invasive, urine-based genomic biomarker tests help urologists detect bladder cancer and monitor for recurrence with greater confidence. A haematuria pathway enabled by the test is now increasingly being used in primary care to help safety rule out the disease, reducing the need for referral.
